» Articles » PMID: 35419052

Risk Factors for Worsening of Bone Loss in Patients Newly Diagnosed with Inflammatory Bowel Disease

Overview
Publisher Wiley
Specialty Gastroenterology
Date 2022 Apr 14
PMID 35419052
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Bone loss is common in patients with inflammatory bowel disease (IBD). The aim of the present study was to determine the prevalence of metabolic bone disease in patients newly diagnosed with IBD and to identify the risk factors for bone loss over time.

Methods: We performed a retrospective, both cross-sectional and longitudinal, study to extract the risk factors of bone loss (including osteopenia and osteoporosis) in patients newly diagnosed with IBD, using dual-energy X-ray absorptiometry (DXA).

Results: A total of 639 patients newly diagnosed with IBD that had at least one DXA were included in the cross-sectional study. Osteopenia and osteoporosis were diagnosed in 24.6% and 5.4% of patients, respectively. Age at diagnosis, body mass index, and serum phosphorus were identified as independent factors associated with bone loss at baseline. A total of 380 of the 639 IBD patients (including 212 CD patients and 168 UC patients) with at least a second DXA scan were included in the longitudinal study. 42.6% of the patients presented a worsening of bone loss in the follow-up study. Menopause, albumin, and use of corticosteroids were identified as independent factors associated with worsening of bone loss.

Conclusions: Metabolic bone disease is common in IBD patients, and there is a significant increase in prevalence of bone loss over time. Postmenopausal female, malnourished patients, and those requiring corticosteroid treatment are at risk for persistent bone loss. Therefore, BMD measurements and early intervention with supplementation of calcium and vitamin D are recommended in IBD patients with high-risk factors.

Citing Articles

Impact of Folate Intake on Bone Mineral Density in Patients with Inflammatory Bowel Disease.

Ratajczak-Pawlowska A, Szymczak-Tomczak A, Michalak M, Rychter A, Zawada A, Skoracka K Nutrients. 2024; 16(1).

PMID: 38201836 PMC: 10780763. DOI: 10.3390/nu16010006.


Risk Factors of Low Bone Mineral Density in Newly Diagnosed Pediatric Inflammatory Bowel Disease.

Ahn M, Yoo I Nutrients. 2023; 15(24).

PMID: 38140307 PMC: 10746078. DOI: 10.3390/nu15245048.


Identifying microbial signatures for patients with postmenopausal osteoporosis using gut microbiota analyses and feature selection approaches.

Huang D, Wang J, Zeng Y, Li Q, Wang Y Front Microbiol. 2023; 14:1113174.

PMID: 37077242 PMC: 10106639. DOI: 10.3389/fmicb.2023.1113174.

References
1.
Ezzat Y, Hamdy K . The frequency of low bone mineral density and its associated risk factors in patients with inflammatory bowel diseases. Int J Rheum Dis. 2010; 13(3):259-65. DOI: 10.1111/j.1756-185X.2010.01542.x. View

2.
Rebello D, Anjelly D, Grand D, Machan J, Beland M, Furman M . Opportunistic screening for bone disease using abdominal CT scans obtained for other reasons in newly diagnosed IBD patients. Osteoporos Int. 2018; 29(6):1359-1366. DOI: 10.1007/s00198-018-4444-6. View

3.
. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994; 843:1-129. View

4.
Miranda-Bautista J, Verdejo C, Diaz-Redondo A, Breton I, Bellon J, Perez-Valderas M . Metabolic bone disease in patients diagnosed with inflammatory bowel disease from Spain. Therap Adv Gastroenterol. 2019; 12:1756284819862152. PMC: 6669853. DOI: 10.1177/1756284819862152. View

5.
Miheller P, Lorinczy K, Lakatos P . Clinical relevance of changes in bone metabolism in inflammatory bowel disease. World J Gastroenterol. 2010; 16(44):5536-42. PMC: 2992671. DOI: 10.3748/wjg.v16.i44.5536. View